| Sep 11 |
Peering Into Mira Pharmaceuticals's Recent Short Interest
|
| Sep 11 |
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
|
| Aug 26 |
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
|
| Aug 26 |
MIRA Announces Significant Test Results
|
| Aug 26 |
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
|
| Aug 14 |
MIRA Continues to Reveal Advances in Treatment
|
| Aug 13 |
MIRA Pharmaceuticals files $100M mixed securities shelf
|
| Aug 12 |
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
|
| Aug 5 |
PayPal, Kellanova upgraded: Wall Street's top analyst calls
|
| Aug 1 |
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
|
